First to the future of cardiac PET


CHICAGO, IL – October 11, 2013 (PRNewswire) – Positron Corporation (OTCBB:POSC) is proud to announce its wholly owned subsidiary, Manhattan Isotope Technology, has received ISO 9001 certification for the production of radioisotopes. ISO is the International Organization for Standardization.  The ISO 9001 international standard is recognized globally as the quality management standard. With this accredited certification, Positron joins a globally recognized consortium of companies demonstrating excellence in a well-managed and customer-focused delivery of products.

Positron has invested significant resources to implement a solid quality management program essential to ensure the delivery of quality, reliable, radioisotope products that conform to customer, statutory, and regulatory requirements.  Achieving ISO 9001:2008 certification is validation of Positron’s commitment to ensuring that our radioisotope products consistently meet product specifications and is applied to our product development, manufacturing, delivery, business practices and customer satisfaction.

ISO certification is essential as Positron collaborates with global suppliers and customers. Positron is able to represent to its customers that its radioisotope products are manufactured under stringent quality requirements and that our suppliers also meet quality criteria. As the only ISO certified supplier of strontium-82 in the United States, Positron certifiably operates to the same quality standards as its customers. 

Suzanne Kitten, Director of Radioisotope Operations of Positron Corporation, states, “This certification represents an important benchmark for Positron as a quality-committed supplier in the strontium-82 arena. Positron is defining radioisotope production excellence; commitment to the ISO endorsement is confirmation of our capability to produce a quality product for the nuclear medicine industry.”

“We continue to make great strides in our privatization of strontium-82 production,” stated, Jason Kitten, Executive Director of Radioisotopes of Positron Corporation. “Our goal was not only to set the quality stage for private production of medical radioisotopes, but to redefine the industry’s expectations.  Our team brings unique, qualified expertise along with decades of experience to Positron’s radioisotope production capabilities and achieving ISO certification is the perfect complement to our strontium-82 product.”

About Positron:

Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiology; providing an end-to-end solution for cardiac PET.  Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron’s unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology.  Positron is redefining the industry.  More information about Positron is available at

Forward Looking Statements: 

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

For more information, contact:

Positron Corporation

Print this page